Double-Digit Growth Stocks
Companies achieving revenue growth of 20% or more year-over-year, among the fastest growers in the S&P 500.
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
887 Companies Meeting Criteria
Showing 301–350 of 887 companies, ranked by Revenue Growth.
| # | Company | Sector | Revenue Growth | Revenue |
|---|---|---|---|---|
| 301 | HDSNHUDSON TECHNOLOGIES INC /NY | - | 68.7% | - |
| 302 | LCIDLucid Group, Inc. | Consumer Discretionary | 67.6% | $808M |
| 303 | BLMHBLUM HOLDINGS, INC. | - | 67.5% | - |
| 304 | TBPHTheravance Biopharma, Inc. | Health Care | 66.9% | $64M |
| 305 | WTMWHITE MOUNTAINS INSURANCE GROUP LTD | Financials | 66.8% | $2.2B |
| 306 | INSMINSMED Inc | Health Care | 66.7% | $364M |
| 307 | TRTN-PATriton International Ltd | - | 66.7% | - |
| 308 | ABEOABEONA THERAPEUTICS INC. | - | 66.3% | - |
| 309 | CPMDCANNAPHARMARX, INC. | - | 66.1% | - |
| 310 | SEZLSezzle | Financials | 66.1% | $419M |
| 311 | ACONAclarion, Inc. | - | 65.6% | - |
| 312 | AXSMAxsome Therapeutics, Inc. | Health Care | 65.5% | $386M |
| 313 | SXTP60 DEGREES PHARMACEUTICALS, INC. | - | 65.5% | - |
| 314 | NVDANvidia | Information Technology | 65.5% | $187.1B |
| 315 | PVLAPALVELLA THERAPEUTICS, INC. | Health Care | 65.3% | $43M |
| 316 | RMCORoyalty Management Holding Corp | - | 65.2% | - |
| 317 | ALNYALNYLAM PHARMACEUTICALS, INC. | Health Care | 65.2% | $2.2B |
| 318 | NVAXNOVAVAX INC | Health Care | 64.7% | $682M |
| 319 | IDRIdaho Strategic Resources, Inc. | Materials | 64.6% | $26M |
| 320 | KULRKULR Technology Group, Inc. | - | 64.5% | - |
| 321 | RIGLRIGEL PHARMACEUTICALS INC | Health Care | 64.1% | $179M |
| 322 | UPSTUpstart Holdings, Inc. | Financials | 64.0% | $637M |
| 323 | EDITEditas Medicine, Inc. | - | 63.9% | - |
| 324 | EQTEQT Corporation | Energy | 63.9% | $7.9B |
| 325 | CRCLCircle Internet Group, Inc. | Financials | 63.9% | - |
| 326 | MDAISpectral AI, Inc. | - | 63.8% | - |
| 327 | HRGNHarvard Apparatus Regenerative Technology, Inc. | - | 63.7% | - |
| 328 | MINDMIND TECHNOLOGY, INC | - | 63.7% | - |
| 329 | SSRMSSR MINING INC. | Financials | 63.7% | $996M |
| 330 | COFSCHOICEONE FINANCIAL SERVICES INC | - | 63.6% | - |
| 331 | MSGMMotorsport Games Inc. | - | 63.5% | - |
| 332 | UNGUnited States Natural Gas Fund, LP | - | 63.5% | - |
| 333 | TRDAEntrada Therapeutics, Inc. | - | 63.4% | - |
| 334 | BKTIBK Technologies Corp | - | 63.3% | - |
| 335 | ONAROnar Holding Corp | - | 62.8% | - |
| 336 | KEYKeyCorp | Financials | 62.7% | $6.4B |
| 337 | OFIXOrthofix Medical Inc. | - | 62.1% | - |
| 338 | VNOMViper Energy | Energy | 62.0% | - |
| 339 | XZOExzeo Group, Inc. | Financials | 62.0% | - |
| 340 | CWANClearwater Analytics Holdings, Inc. | Information Technology | 61.9% | $640M |
| 341 | ACATNP Life Sciences Health Industry Group Inc. | - | 61.4% | - |
| 342 | SITMSiTime | Information Technology | 61.2% | $281M |
| 343 | CTRECareTrust REIT, Inc. | Real Estate | 60.8% | $296M |
| 344 | IOVAIOVANCE BIOTHERAPEUTICS, INC. | Health Care | 60.6% | $164M |
| 345 | LGNDLigand Pharmaceuticals, Inc. | Health Care | 60.4% | $251M |
| 346 | LGNDZLIGAND PHARMACEUTICALS INC | - | 60.4% | - |
| 347 | KNSAKiniksa Pharmaceuticals International, plc | Health Care | 60.1% | $423M |
| 348 | SNWVSANUWAVE Health, Inc. | - | 60.0% | - |
| 349 | RGTIRigetti Computing, Inc. | Information Technology | 59.9% | $13M |
| 350 | DAVEDave Inc./DE | Financials | 59.7% | $347M |
What Drives Double-Digit Growth?
Sustained revenue growth above 20% in large-cap companies is exceptional and usually driven by secular tailwinds, disruptive technology, or rapid market share gains. While impressive, high growth rates often normalize over time as companies scale and markets mature.
YoY Revenue Growth > 20%
Results are based on SEC EDGAR filings. Companies with missing, unreliable, or extreme outlier values are excluded from screening.
Related Rankings
See the top companies ranked by these related metrics